CoChat

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Open access

Published version of a preprint

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index; 1 of the 35 sources its claims cite were checked for support.

Abstract

Purpose: MEK inhibitors (MEKi) lack monotherapy efficacy in most RAS-mutant cancers. BCL-xL is an anti-apoptotic protein identified by a synthetic lethal shRNA screen as a key suppressor of apoptotic response to MEKi. Patients and Methods: We conducted a dose escalation study (NCT02079740) of the BCL-xL inhibitor navitoclax and MEKi trametinib in patients with RAS-mutant tumors with expansion cohorts for: pancreatic, gynecologic (GYN), non–small cell lung cancer (NSCLC), and other cancers harboring KRAS/NRAS mutations. Paired pretreatment and day 15 tumor biopsies and serial cell-free (cf)DNA were analyzed. Results: A total of 91 patients initiated treatment, with 38 in dose escalation. Fifty-eight percent had ≥3 prior therapies. A total of 15 patients (17%) had colorectal cancer, 19 (11%) pancreatic, 15 (17%) NSCLC, and 32 (35%) GYN cancers. The recommended phase II dose (RP2D) was established as trametinib 2 mg daily days 1 to 14 and navitoclax 250 mg daily days 1 to 28 of each cycle. Most common adverse events included diarrhea, thrombocytopenia, increased AST/ALT, and acneiform rash. At RP2D, 8 of 49 (16%) evaluable patients achieved partial response (PR). Disease-specific differences in efficacy were noted. In patients with GYN at the RP2D, 7 of 21 (33%) achieved a PR and median duration of response 8.2 months. No PRs occurred in patients with colorectal cancer, NSCLC, or pancreatic cancer. MAPK pathway inhibition was observed in on-treatment tumor biopsies. Reductions in KRAS/NRAS mutation levels in cfDNA correlated with clinical benefit. Conclusions: Navitoclax in combination with trametinib was tolerable. Durable clinical responses were observed in patients with RAS-mutant GYN cancers, warranting further evaluation in this population.

Overview

CoChat Summary

TL;DR

In this phase I/II trial, combined BCL-xL inhibition with navitoclax and MEK inhibition with trametinib was tolerable in KRAS/NRAS-mutant advanced solid tumors and produced durable responses in gynecologic cancers but not in colorectal, pancreatic, or NSCLC. At the RP2D, 8/49 evaluable patients (16%) had a partial response, including 7/21 (33%) with GYN cancers and median duration of response 8.2 months.

Key findings

  • The RP2D was navitoclax 250 mg daily on days 1–28 of each cycle after a 150 mg lead-in on days 1–7 of cycle 1, plus trametinib 2 mg daily on days 1–14 of each cycle. Among 91 treated patients, common TEAEs included diarrhea (62/85, 72.9%), platelet count decreased (60/85, 70.6%), AST increased (58/85, 68.2%), and acneiform rash (51/85, 60.0%); grade ≥3 thrombocytopenia occurred in only 2 patients (2%).
  • At the RP2D, 8/49 (16%) evaluable patients achieved PR and 29/49 (59%) achieved clinical benefit. Disease-specific activity was striking in GYN cancers: 7/21 (33%) evaluable patients at RP2D achieved confirmed PR, with median DOR 8.17 months; no PRs occurred in colorectal (n = 13), pancreatic (n = 16), or NSCLC (n = 13), while one NRAS-mutant melanoma patient also achieved PR.
  • GYN cancers had longer median PFS than all other tumor types (4.8 vs. 1.87 months, P = 0.0025) and longer median OS (18.13 vs. 6.57 months, P = 0.022).
  • In serial cfDNA from 53 expansion patients, a ≥30% decrease in KRAS/NRAS mutation levels at 4 weeks occurred in 21 patients; 16/21 (76%) achieved clinical benefit, and only 2/21 patients with PD (10%) had such a decrease. A ≥30% decrease was associated with longer median PFS (4.8 vs. 1.81 months, P = 0.0014) and OS (18.13 vs. 6.63 months, P = 0.013). MAPK pathway suppression was greater in patients with clinical benefit than in those with PD, but was less than in BRAFV600-mutant melanoma treated with BRAF inhibitor therapy.

Methods

  • Phase I/II, open-label study (NCT02079740) at Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute. Part I used a 3+3 dose escalation of navitoclax plus trametinib across three schedules; Part II enrolled expansion cohorts at the RP2D for pancreatic, GYN, NSCLC, and other NRAS-mutant cancers using a Simon two-stage design.
  • Eligible patients had KRAS- or NRAS-mutant metastatic/unresectable malignancy affecting codons 12, 13, 61, or 146, ECOG 0–1, measurable disease, and at least one prior systemic chemotherapy. A total of 91 patients were treated (38 in dose escalation, 53 in expansion).
  • Antitumor efficacy was assessed by CT/MRI every 8 weeks using RECIST v1.1. Paired pretreatment and day 15 tumor biopsies were analyzed by qRT-PCR for MAPK-regulated transcripts; serial plasma cfDNA was analyzed by mutant-specific droplet digital PCR for KRAS/NRAS mutations.

Limitations

  • Stated: small sample sizes for certain individual tumor types, especially within GYN subtypes, precluded thorough assessment of activity in each group; more comprehensive dose-schedule optimization was warranted.
  • Stated: limited biopsy tissue allowed analysis only of MAPK-regulated transcripts, not parallel protein markers, and the biopsy sample size was too small to conclusively compare MAPK inhibition across tumor types.
  • Evident from the text: this was a single-arm, nonrandomized study without a comparator; the NSCLC cohort terminated early due to slow accrual and lack of efficacy, and the planned colorectal expansion cohort was replaced with GYN based on lack of efficacy in colorectal cancer.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-23-3135

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Study design. A, Study schema for part 1 dose escalation and CONSORT diagram. Specific dose levels, dosing schedule, and patients enrolled are shown. B, Study schema for part 2 dose expansion cohorts and CONSORT diagram. Specific tumor types and patients enrolled are shown.
Figure 1. Study design. A, Study schema for part 1 dose escalation and CONSORT diagram. Specific dose levels, dosing schedule, and patients enrolled are shown. B, Study schema for part 2 dose expansion cohorts and CONSORT diagram. Specific tumor types and patients enrolled are shown.CC BY-NC-ND · PubMed Central
Figure 2. Clinical efficacy. A, Best tumor response by RECIST in all patients at all dose levels, shown by tumor type. B, Best tumor response by RECIST in patients treated at the RP2D, shown by tumor type. C–F, Best tumor response by RECIST in patients treated at all dose levels with (C) colorectal cancer, (D) pancreatic ductal adenocarcinoma (PDAC), (E) NSCLC, and (F) GYN cancers. Patients treated at the RP2D are indicated with a red diamond.
Figure 2. Clinical efficacy. A, Best tumor response by RECIST in all patients at all dose levels, shown by tumor type. B, Best tumor response by RECIST in patients treated at the RP2D, shown by tumor type. C–F, Best tumor response by RECIST in patients treated at all dose levels with (C) colorectal cancer, (D) pancreatic ductal adenocarcinoma (PDAC), (E) NSCLC, and (F) GYN cancers. Patients treated at the RP2D are indicated with a red diamond.CC BY-NC-ND · PubMed Central
Figure 3. Time on treatment and PFS and OS. A, Swim plot of patients showing time on treatment by tumor type. Time of first response is indicated by a black triangle and patients still ongoing on treatment at the time of the data cut are indicated with an arrow. B and C, Kaplan–Meyer curves for (B) PFS and (C) OS are shown for patients with GYN versus non-GYN tumor types with associated P values.
Figure 3. Time on treatment and PFS and OS. A, Swim plot of patients showing time on treatment by tumor type. Time of first response is indicated by a black triangle and patients still ongoing on treatment at the time of the data cut are indicated with an arrow. B and C, Kaplan–Meyer curves for (B) PFS and (C) OS are shown for patients with GYN versus non-GYN tumor types with associated P values.CC BY-NC-ND · PubMed Central
Figure 4. Serial ctDNA analysis and MAPK pathway inhibition in paired tumor biopsies. A, Percent change in KRAS or NRAS mutant allele-fraction in ctDNA after 4 weeks of treatment, relative to pre-treatment levels, in patients achieving clinical benefit (defined as PR or SD) versus PD on first restaging scan. B, PFS and OS for patients who achieved a 30% or greater decrease in ctDNA levels by 4 weeks, relative to pretreatment levels, compared with patients who did not. C and D, Examples of patients with (C) ovarian cancer and (D) cervical cancer who achieved durable partial responses. Serial monitoring of tumor-specific NRAS or KRAS mutation allele fraction in ctDNA throughout treatment is shown, along with CT scans from baseline, response nadir, and progression with lesions indicated. E, The degree of MAPK pathway suppression was assessed by measurement of MAPK-regulated transcript levels in each patient's day 15 tumor biopsy relative to the paired pretreatment biopsy. Patients from this study were compared with similar paired pre- and on-treatment tumor biopsies obtained from BRAFV600 mutant melanoma treated with BRAF inhibitor therapy with or without MEK inhibitor. F, The degree of MAPK pathway suppression achieved by day 15 of treatment was compared between patients achieving PR or SD versus PD on first restating scan, with individual tumor types indicated.
Figure 4. Serial ctDNA analysis and MAPK pathway inhibition in paired tumor biopsies. A, Percent change in KRAS or NRAS mutant allele-fraction in ctDNA after 4 weeks of treatment, relative to pre-treatment levels, in patients achieving clinical benefit (defined as PR or SD) versus PD on first restaging scan. B, PFS and OS for patients who achieved a 30% or greater decrease in ctDNA levels by 4 weeks, relative to pretreatment levels, compared with patients who did not. C and D, Examples of patients with (C) ovarian cancer and (D) cervical cancer who achieved durable partial responses. Serial monitoring of tumor-specific NRAS or KRAS mutation allele fraction in ctDNA throughout treatment is shown, along with CT scans from baseline, response nadir, and progression with lesions indicated. E, The degree of MAPK pathway suppression was assessed by measurement of MAPK-regulated transcript levels in each patient's day 15 tumor biopsy relative to the paired pretreatment biopsy. Patients from this study were compared with similar paired pre- and on-treatment tumor biopsies obtained from BRAFV600 mutant melanoma treated with BRAF inhibitor therapy with or without MEK inhibitor. F, The degree of MAPK pathway suppression achieved by day 15 of treatment was compared between patients achieving PR or SD versus PD on first restating scan, with individual tumor types indicated.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 17 Not checked · 78 Own results and interpretations

65 more claims

Create a free account to see all 96 claims and to verify the 34 references still open.

See all claims — free account
  • It may state two separate claims as one. 14
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 27 references

Cited by

See all 46

Metadata

Authors
Corcoran, R. B., Do, K. T., Kim, J. E., Cleary, J. M., Parikh, A. R., Yeku, O. O., Xiong, N., Weekes, C. D., Veneris, J., Ahronian, L. G., Mauri, G., Tian, J., Norden, B. L., Michel, A. G., Van Seventer, E. E., Siravegna, G., Camphausen, K., Chi, G., Fetter, I. J., Brugge, J. S., Chen, H., Takebe, N., Penson, R. T., Juric, D., Flaherty, K. T., Sullivan, R. J., Clark, J. W., Heist, R. S., Matulonis, U. A., Liu, J. F., & Shapiro, G. I.
Affiliations
  • Harvard University (US)
  • Dana-Farber Cancer Institute (US)
  • 1Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • National Institutes of Health (US)
Corresponding author
Corcoran, Ryan B.
Venue
Clinical Cancer Research
Published
2024-03-08
Volume
30
Issue
9
Pages
1739-1749
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4392586352
Cited by
46
References
28
Citations by year
2026: 16 · 2025: 15 · 2024: 8
FWCI
3.78
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (UM1 CA186709, U54 CA224068, P50 CA240243)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
navitoclax, trametinib, BCL-XL inhibition, MEK inhibition, KRAS mutation, NRAS mutation, RAS-mutant cancers, gynecologic cancer, synthetic lethality, MAPK inhibition, circulating tumor DNA, combination therapy, dose escalation, advanced solid tumors
MeSH terms
Adult, Aged, Aged, 80 and over, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Pyridones, Pyrimidinones, Sulfonamides, Proto-Oncogene Proteins p21(ras), Treatment Outcome, GTP Phosphohydrolases, Protein Kinase Inhibitors, bcl-X Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-23-3135
The paper
Corcoran, R. B., Do, K. T., Kim, J. E., Cleary, J. M., Parikh, A. R., Yeku, O. O., Xiong, N., Weekes, C. D., Veneris, J., Ahronian, L. G., Mauri, G., Tian, J., Norden, B. L., Michel, A. G., Van Seventer, E. E., Siravegna, G., Camphausen, K., Chi, G., Fetter, I. J., . . . Shapiro, G. I. (2024). Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-3135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.